Acquired resistance to EGFR-targeted therapies in colorectal cancer

Cetuximab and panitumumab are anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies used as therapies for metastatic colorectal cancer patients. Intrinsic mechanisms of resistance, such as RAS mutations, can prevent patients from having a response with clinical benefit. The clinica...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular oncology 2014-09, Vol.8 (6), p.1084-1094
Hauptverfasser:	Van Emburgh, Beth O., Sartore-Bianchi, Andrea, Di Nicolantonio, Federica, Siena, Salvatore, Bardelli, Alberto
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired resistance AKT protein Animals Anti-EGFR therapy Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Biomarkers Cancer therapies Cetuximab Colon - drug effects Colon - metabolism Colon - pathology Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - metabolism Colorectal Neoplasms - pathology Drug Resistance, Neoplasm Epidermal growth factor Epidermal growth factor receptors ErbB Receptors - antagonists & inhibitors ErbB Receptors - metabolism Extracellular signal-regulated kinase Humans Immunoglobulins Immunotherapy Kinases MAP Kinase Signaling System - drug effects MET Metastases Metastasis Molecular Targeted Therapy Monoclonal antibodies Mutation Panitumumab Proto-Oncogene Proteins c-akt - metabolism Raf protein RAS ras Proteins - metabolism Rectum - drug effects Rectum - metabolism Rectum - pathology Review Reviews Signal transduction Signal Transduction - drug effects Targeted cancer therapy Tumor cells Tyrosine Vascular endothelial growth factor Xenografts
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!